Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have been ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.